Stories

Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.

Sickle cell disease disproportionately affects babies in Africa, but many go undiagnosed due to lack of screening. Newborn screening is needed to save lives and improve care.

Raising awareness of the ways in which prostate cancer can affect the sexual minority and gender minority communities.

Inspired by Emily Whitehead, along with other early patients treated with CAR-T cell therapy, Novartis embarked on a pioneering journey to reimagine cancer treatment. After 10 years, we continue to relentlessly pursue new science around cell and gene therapies to transform the lives of patients today and in the future.

Low- and middle-income countries will account for some three in four of the world’s cancer deaths within the next decade without better access to care. It’s a gap Amy Israel and her team at Novartis are trying to bridge.

Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.

Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.